Prognosia Breast, an AI-driven mammography tool, receives FDA Breakthrough Device status for improved five-year breast cancer risk prediction.
Key Details
- 1FDA granted Breakthrough Device designation to Prognosia Breast, an AI mammography analysis tool.
- 2Developed by Washington University School of Medicine experts.
- 3Tool predicts five-year breast cancer risk from mammogram findings.
- 4Claims to be twice as accurate as current risk assessment methods.
- 5Aims to inform decisions on supplemental imaging and genetic testing.
Why It Matters
FDA's recognition accelerates the path for advanced AI-enabled risk assessment in breast cancer screening. Improved prediction can enhance early intervention and personalisation, potentially reducing morbidity and mortality.
Source
Health Imaging
Related News
•Radiology Business
Google Mammography AI Matches Radiologists, Boosts Efficiency in NHS Study
Google's mammography AI proved as effective or better than radiologists in detecting breast cancer while reducing interpretation time.
•Radiology Business
Cognita CXR AI Receives FDA Breakthrough Device Designation
Radiology Partners' Cognita Chest X-ray AI tool earns FDA Breakthrough Device status for multiple clinical uses.
•AuntMinnie
AI Model on Mammograms Predicts Women's Cardiovascular Risk
AI-driven quantification of breast arterial calcification (BAC) on mammograms predicts risk of major cardiovascular events in women, independent of traditional risk scores.